Blackrock Neurotech
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Blackrock Neurotech - overview
Established
2008
Location
Salt Lake City, UT, US
Primary Industry
Medical Devices & Equipment
About
Blackrock Neurotech, based in the US, focuses on developing advanced brain-computer interface (BCI) technologies to improve the autonomy of individuals with neurological disorders. Founded in 2008, Blackrock Neurotech is dedicated to creating innovative BCI solutions for users with paralysis and other neurological challenges. The company operates out of Salt Lake City, US. The founders, Florian Solzbacher and Marcus Gerhardt, have a background in neurotechnology.
Most recently, Blackrock Neurotech secured USD 12. 37 mn in Series B funding on April 29, 2024, from Tether Limited, bringing the total amount raised to USD 12. 37 mn with a current valuation of USD 325. 69 mn.
Blackrock Neurotech specializes in advanced brain-computer interface (BCI) technology designed to enhance the quality of life for individuals with paralysis and other neurological disorders. The company's flagship product, the MoveAgain BCI, is a clinical device that enables users to execute various tasks through thought alone, allowing for activities such as eating, drinking, and operating robotic arms using brain signals. The MoveAgain BCI has been utilized in over 1,000 research institutions globally, significantly impacting markets across North America, Europe, and Asia. Blackrock Neurotech primarily generates revenue through sales of its BCI devices and custom solutions to research institutions and healthcare providers.
The company partners with healthcare facilities and academic institutions to provide technology for clinical and research applications, utilizing a pricing structure tailored for institutional buyers. Future revenue opportunities may include subscription models or extended service agreements. The recent Series B funding of USD 12. 37 mn will be utilized to boost the commercialization of Blackrock Neurotech's medical devices.
The company aims to expand its market reach into new regions, with specific plans targeting additional markets in Europe and Asia by the end of 2025. Blackrock Neurotech is also in the process of developing new products aimed at further enhancing the functionalities of its BCI technologies.
Current Investors
Presight Capital, re.Mind Capital, Sorenson Impact
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic Equipment, Medical Software
Website
www.blackrockneurotech.com/
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.